Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AUPH logo AUPH
Upturn stock ratingUpturn stock rating
AUPH logo

Aurinia Pharmaceuticals Inc (AUPH)

Upturn stock ratingUpturn stock rating
$12.08
Last Close (24-hour delay)
Profit since last BUY30.74%
upturn advisory
Strong Buy
BUY since 21 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: AUPH (3-star) is a STRONG-BUY. BUY since 21 days. Profits (30.74%). Updated daily EoD!

Upturn Star Rating

rating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

6 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $11.71

1 Year Target Price $11.71

Analysts Price Target For last 52 week
$11.71 Target price
52w Low $6.42
Current$12.08
52w High $12.53

Analysis of Past Performance

Type Stock
Historic Profit -4.22%
Avg. Invested days 35
Today’s Advisory Strong Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.59B USD
Price to earnings Ratio 28.09
1Y Target Price 11.71
Price to earnings Ratio 28.09
1Y Target Price 11.71
Volume (30-day avg) 6
Beta 1.24
52 Weeks Range 6.42 - 12.53
Updated Date 08/29/2025
52 Weeks Range 6.42 - 12.53
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.43

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-07-31
When -
Estimate 0.14
Actual 0.16

Profitability

Profit Margin 23.31%
Operating Margin (TTM) 28.85%

Management Effectiveness

Return on Assets (TTM) 7.69%
Return on Equity (TTM) 17.33%

Valuation

Trailing PE 28.09
Forward PE 19.05
Enterprise Value 1356781915
Price to Sales(TTM) 6.11
Enterprise Value 1356781915
Price to Sales(TTM) 6.11
Enterprise Value to Revenue 5.22
Enterprise Value to EBITDA 15.69
Shares Outstanding 131630000
Shares Floating 128061069
Shares Outstanding 131630000
Shares Floating 128061069
Percent Insiders 7.15
Percent Institutions 45.58

ai summary icon Upturn AI SWOT

Aurinia Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Aurinia Pharmaceuticals Inc. was founded in 2006. The company is focused on developing and commercializing therapies to treat autoimmune diseases, particularly lupus nephritis.

business area logo Core Business Areas

  • Lupus Nephritis: The company's primary focus is on the development and commercialization of therapies for lupus nephritis (LN), a serious kidney disease caused by systemic lupus erythematosus (SLE).

leadership logo Leadership and Structure

Peter Greenleaf is the President and Chief Executive Officer. The company has a typical corporate structure with departments such as research and development, commercial operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • LUPKYNIS (voclosporin): LUPKYNIS is Aurinia's only FDA-approved drug, used for the treatment of adult patients with active lupus nephritis in combination with a background immunosuppressive therapy regimen. As of the last market report, LUPKYNIS had approximately 25% market share in the LN treatment landscape. Competitors include Benlysta (belimumab) and cyclophosphamide. Revenue from this product accounts for almost the entirety of Aurinia's revenue.

Market Dynamics

industry overview logo Industry Overview

The market for lupus nephritis treatments is growing, driven by increasing awareness of the disease and the availability of new therapies. The industry is competitive, with several companies developing and marketing treatments for LN.

Positioning

Aurinia is positioned as a key player in the LN market, primarily based on the first oral therapy for the disease, LUPKYNIS. The company's competitive advantage lies in the efficacy and convenience of its treatment.

Total Addressable Market (TAM)

The total addressable market for lupus nephritis is estimated to be several billion dollars annually. Aurinia is positioned to capture a significant portion of this market with LUPKYNIS.

Upturn SWOT Analysis

Strengths

  • FDA-approved therapy for lupus nephritis (LUPKYNIS)
  • Strong intellectual property protection for LUPKYNIS
  • Experienced management team
  • Focused on a specific therapeutic area

Weaknesses

  • Reliance on a single product (LUPKYNIS)
  • Relatively small company size compared to competitors
  • Market acceptance and uptake of LUPKYNIS
  • Need to expand market share

Opportunities

  • Expansion of LUPKYNIS label to include other indications
  • Partnerships or collaborations with larger pharmaceutical companies
  • Growth in the lupus nephritis market
  • Geographic expansion of LUPKYNIS sales

Threats

  • Competition from other lupus nephritis treatments
  • Regulatory hurdles
  • Pricing pressures
  • Patent expiration of LUPKYNIS

Competitors and Market Share

competitor logo Key Competitors

  • GSK (GSK)
  • Roche (RHHBY)
  • Bristol-Myers Squibb (BMY)

Competitive Landscape

Aurinia's advantage lies in having the only oral therapy for lupus nephritis, but faces competition from established players like GSK and Roche with products like Benlysta and CellCept.

Growth Trajectory and Initiatives

Historical Growth: Aurinia's growth has been primarily driven by the commercialization of LUPKYNIS. Historical revenue data can be found in the company's financial reports.

Future Projections: Future growth projections are based on analyst estimates and the company's own guidance. These projections typically include revenue forecasts and EPS growth. These data are updated regularly on financial information sites.

Recent Initiatives: Recent initiatives include efforts to expand the market share of LUPKYNIS and to pursue potential label expansions.

Summary

Aurinia Pharmaceuticals is a pharmaceutical company focusing on lupus nephritis treatment with its drug LUPKYNIS. While LUPKYNIS is a strong asset and a first-in-class treatment with reasonable market share, the company's reliance on a single product poses a significant risk. Increasing competition, pricing pressures, and regulatory hurdles will impact future growth. Overall, Aurinia is moderately positioned within the LN market and must continue to strengthen its balance sheet.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Aurinia Pharmaceuticals Investor Relations
  • SEC Filings
  • Analyst Reports
  • Company Press Releases

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Market share data are estimates and may vary. Financial data should be verified with the company's official reports.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Aurinia Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Edmonton, AB, Canada
IPO Launch date 1999-01-26
President, CEO & Director Mr. Peter S. Greenleaf M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 130
Full time employees 130

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.